Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.41), $0.06 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $19.22 million versus the consensus estimate of $15.37 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.